PCSK9抑制剂的降脂治疗研究进展
Research Progress of PCSK9 Inhibitors in Lipid-Lowering Therapy
DOI: 10.12677/ACM.2023.1381874, PDF,   
作者: 宫 喜：济宁医学院临床医学院，山东 济宁 ；魏子秀*：济宁市第一人民医院心内科，山东 济宁
关键词: PCSK9抑制剂；低密度脂蛋白胆固醇；依洛尤单抗；阿利西尤单抗；PCSK9 Inhibitor； Low-Density Lipoprotein Cholesterol； Evolocumab； Alirocumab
摘要: 低密度脂蛋白胆固醇(LDL-C)水平升高是冠状动脉粥样硬化性心血管疾病(ASCVD)的重要危险因素。他汀类药物仍是当前降脂治疗的基石，经过他汀类药物治疗后，仍有部分高危患者无法降至目标LDL-C水平。前蛋白转化酶枯草杆菌蛋白酶Kexin-9 (PCSK9)是一种参与LDL-C受体降解过程的蛋白酶，已成为降脂治疗的关键靶点。PCSK9抑制剂可通过抑制PCSK9加速LDL-C清除，为降脂治疗提供了新思路，其疗效及安全性已在临床试验中得到证实。本综述对PCSK9作用机制及PCSK9抑制剂临床疗效进行了总结。
Abstract: Elevated low-density lipoprotein cholesterol (LDL-C) level is an important risk factor for atheroscle-rotic cardiovascular disease (ASCVD). Statins are still the cornerstone of current lipid-lowering therapy, and some high-risk patients still cannot reach the target LDL-C level after statin therapy. Proprotein convertase subtilisin kexin type 9 (PCSK9) is a protease involved in the degradation of LDL-C receptors and has become a key target for lipid-lowering therapy. PCSK9 inhibitors can ac-celerate LDL-C clearance by inhibiting PCSK9, and provides a new idea for lipid-lowering therapy, and its efficacy and safety have been confirmed in clinical trials. This review summarizes the mechanism of action of PCSK9 and the clinical efficacy of PCSK9 inhibitors.
文章引用：宫喜, 魏子秀. PCSK9抑制剂的降脂治疗研究进展[J]. 临床医学进展, 2023, 13(8): 13414-13419. https://doi.org/10.12677/ACM.2023.1381874

参考文献

[1] Borén, J., Chapman, M.J., Krauss, R.M., et al. (2020) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement from the European Atheroscle-rosis Society Consensus Panel. European Heart Journal, 41, 2313-2330. [Google Scholar] [CrossRef] [PubMed]
[2] Ference, B.A., Ginsberg, H.N., Graham, I., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472.
[3] Reiner, Z. (2014) Resistance and Intolerance to Statins. Nutrition, Metabolism and Cardi-ovascular Diseases, 24, 1057-1066. [Google Scholar] [CrossRef] [PubMed]
[4] (2013) HPS2-THRIVE Randomized Placebo-Controlled Trial in 25673 High-Risk Patients of ER Niacin/Laropiprant: Trial Design, Pre-Specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment. European Heart Journal, 34, 1279-1291. [Google Scholar] [CrossRef] [PubMed]
[5] Giugliano, R.P. and Sabatine, M.S. (2015) Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? Journal of the American College of Cardiology, 65, 2638-2651. [Google Scholar] [CrossRef] [PubMed]
[6] 王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
[7] Seidah, N.G., Benjannet, S., Wickham, L., et al. (2003) The Secretory Propro-tein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 100, 928-933. [Google Scholar] [CrossRef] [PubMed]
[8] Cuchel, M., Bruckert, E., Ginsberg, H.N., et al. (2014) Homozy-gous Familial Hypercholesterolaemia: New Insights and Guidance for Clinicians to Improve Detection and Clinical Management. A Position Paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Athero-sclerosis Society. European Heart Journal, 35, 2146-2157. [Google Scholar] [CrossRef] [PubMed]
[9] Kent, S.T., Rosenson, R.S., Avery, C.L., et al. (2017) PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data from 9 Studies of Blacks and Whites. Circulation-Cardiovascular Genetics, 10, e1632. [Google Scholar] [CrossRef] 
[10] Seidah, N.G. and Prat, A. (2002) Precursor Convert-ases in the Secretory Pathway, Cytosol and Extracellular Milieu. Essays in Biochemistry, 38, 79-94. [Google Scholar] [CrossRef] [PubMed]
[11] Naureckiene, S., Ma, L., Sreekumar, K., et al. (2003) Functional Charac-terization of Narc 1, a Novel Proteinase Related to Proteinase K. Archives of Biochemistry and Biophysics, 420, 55-67. [Google Scholar] [CrossRef] [PubMed]
[12] Lambert, G., Sjouke, B., Choque, B., et al. (2012) The PCSK9 Decade. Journal of Lipid Research, 53, 2515-2524. [Google Scholar] [CrossRef] 
[13] Qian, Y.W., Schmidt, R.J., Zhang, Y., et al. (2007) Secreted PCSK9 Downregulates Low Density Lipoprotein Receptor through Receptor-Mediated Endocytosis. Journal of Lipid Research, 48, 1488-1498. [Google Scholar] [CrossRef] 
[14] Kwon, H.J., Lagace, T.A., McNutt, M.C., et al. (2008) Molecu-lar Basis for LDL Receptor Recognition by PCSK9. Proceedings of the National Academy of Sciences of the United States of America, 105, 1820-1825. [Google Scholar] [CrossRef] [PubMed]
[15] Poirier, S., Mayer, G., Poupon, V., et al. (2009) Dissection of the Endogenous Cellular Pathways of PCSK9-Induced Low Density Lipoprotein Receptor Degradation: Evidence for an In-tracellular Route. Journal of Biological Chemistry, 284, 28856-28864. [Google Scholar] [CrossRef] 
[16] Watts, G.F., Chan, D.C., Somaratne, R., et al. (2018) Controlled Study of the Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibition with Evolocumab on Lipoprotein(a) Par-ticle Kinetics. European Heart Journal, 39, 2577-2585. [Google Scholar] [CrossRef] [PubMed]
[17] Rice, L.M., Donigan, M., Yang, M., et al. (2014) Protein Phospha-tase 2A (PP2A) Regulates Low Density Lipoprotein Uptake through Regulating Sterol Response Element-Binding Pro-tein-2 (SREBP-2) DNA Binding. Journal of Biological Chemistry, 289, 17268-17279. [Google Scholar] [CrossRef] 
[18] Jeong, H.J., Lee, H.S., Kim, K.S., et al. (2008) Sterol-Dependent Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 Expression by Sterol-Regulatory Element Binding Protein-2. Journal of Lipid Research, 49, 399-409. [Google Scholar] [CrossRef] 
[19] Bedi, M., Niesen, M. and Lopez, D. (2008) Inhibition of Squa-lene Synthase Upregulates PCSK9 Expression in Rat Liver. Archives of Biochemistry and Biophysics, 470, 116-119. [Google Scholar] [CrossRef] [PubMed]
[20] Rashid, S., Curtis, D.E., Garuti, R., et al. (2005) Decreased Plasma Cholesterol and Hypersensitivity to Statins in Mice Lacking Pcsk9. Proceedings of the National Academy of Sciences of the United States of America, 102, 5374-5379. [Google Scholar] [CrossRef] [PubMed]
[21] Careskey, H.E., Davis, R.A., Alborn, W.E., et al. (2008) Atorvas-tatin Increases Human Serum Levels of Proprotein Convertase Subtilisin/Kexin Type 9. Journal of Lipid Research, 49, 394-398. [Google Scholar] [CrossRef] 
[22] Welder, G., Zineh, I., Pacanowski, M.A., et al. (2010) High-Dose Atorvastatin Causes a Rapid Sustained Increase in Human Serum PCSK9 and Disrupts Its Correlation with LDL Cholesterol. Journal of Lipid Research, 51, 2714-2721. [Google Scholar] [CrossRef] 
[23] Awan, Z., Seidah, N.G., MacFadyen, J.G., et al. (2012) Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: The JUPITER Trial. Clinical Chemistry, 58, 183-189. [Google Scholar] [CrossRef] [PubMed]
[24] Dias, C.S., Shaywitz, A.J., Wasserman, S.M., et al. (2012) Ef-fects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels: Results from 2 Randomized, Double-Blind, Place-bo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. Journal of the American College of Cardiology, 60, 1888-1898. [Google Scholar] [CrossRef] [PubMed]
[25] Keating, G.M. (2016) Evolocumab: A Review in Hyperlipidemia. American Journal of Cardiovascular Drugs, 16, 67-78. [Google Scholar] [CrossRef] [PubMed]
[26] Zhang, X.L., Zhu, Q.Q., Zhu, L., et al. (2015) Safety and Efficacy of Anti-PCSK9 Antibodies: A Meta-Analysis of 25 Random-ized, Controlled Trials. BMC Medicine, 13, Article No. 123. [Google Scholar] [CrossRef] [PubMed]
[27] O’Donoghue, M.L., Giugliano, R.P., Wiviott, S.D., et al. (2022) Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146, 1109-1119. [Google Scholar] [CrossRef] 
[28] Kastelein, J.J., Ginsberg, H.N., Langslet, G., et al. (2015) ODYSSEY FH I and FH II: 78 Week Results with Alirocumab Treatment in 735 Patients with Heterozygous Familial Hypercholesterolaemia. European Heart Journal, 36, 2996-3003. [Google Scholar] [CrossRef] [PubMed]
[29] Schwartz, G.G., Steg, P.G., Szarek, M., et al. (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine, 379, 2097-2107. [Google Scholar] [CrossRef] 
[30] Goodman, S.G., Aylward, P.E., Szarek, M., et al. (2019) Effects of Alirocumab on Cardiovascular Events after Coronary Bypass Surgery. Journal of the American College of Cardiology, 74, 1177-1186. [Google Scholar] [CrossRef] [PubMed]
[31] Ostadal, P., Steg, P.G., Poulouin, Y., et al. (2022) Metabolic Risk Factors and Effect of Alirocumab on Cardiovascular Events after Acute Coronary Syndrome: A Post-Hoc Analysis of the Odyssey Outcomes Randomised Controlled Trial. The Lancet Diabetes & Endocrinology, 10, 330-340. [Google Scholar] [CrossRef] 
[32] Jukema, J.W., Zijlstra, L.E., Bhatt, D.L., et al. (2019) Effect of Alirocumab on Stroke in Odyssey Outcomes. Circulation, 140, 2054-2062. [Google Scholar] [CrossRef] 
[33] Fitzgerald, K., Frank-Kamenetsky, M., Shul-ga-Morskaya, S., et al. (2014) Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtil-isin/Kexin Type 9 (PCSK9) and the Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial. The Lancet, 383, 60-68. [Google Scholar] [CrossRef] 
[34] Lo, S.P., Bottomley, M.J., Calzetta, A., et al. (2011) Mecha-nistic Implications for LDL Receptor Degradation from the PCSK9/LDLR Structure at Neutral pH. EMBO Reports, 12, 1300-1305. [Google Scholar] [CrossRef] [PubMed]
[35] Ray, K.K., Landmesser, U., Leiter, L.A., et al. (2017) In-clisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. The New England Journal of Medicine, 376, 1430-1440. [Google Scholar] [CrossRef] 
[36] Wright, R.S., Collins, M.G., Stoekenbroek, R.M., et al. (2020) Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clinic Proceedings, 95, 77-89. [Google Scholar] [CrossRef] [PubMed]

为你推荐